Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for once-monthly TransCon Semaglutide are only one part of the Ascendis story. Take a look at 1 major warning sign we have identified for Ascendis Pharma.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.